Insider Selling: Croda International Plc (LON:CRDA) Insider Sells 380 Shares of Stock

Posted by John Perry on Apr 10th, 2025

Croda International Plc (LON:CRDA – Get Free Report) insider Tom Brophy sold 380 shares of the stock in a transaction on Monday, April 7th. The shares were sold at an average price of GBX 2,643 ($33.77), for a total transaction of £10,043.40 ($12,833.38).

Croda International Price Performance

Shares of LON CRDA opened at GBX 2,642 ($33.76) on Thursday. Croda International Plc has a twelve month low of GBX 2,567 ($32.80) and a twelve month high of GBX 5,034 ($64.32). The business has a 50 day simple moving average of GBX 3,059.10 and a 200-day simple moving average of GBX 3,402.88. The company has a current ratio of 2.72, a quick ratio of 2.25 and a debt-to-equity ratio of 30.90. The company has a market capitalization of £3.69 billion, a price-to-earnings ratio of 22.70, a price-to-earnings-growth ratio of 1.40 and a beta of 0.74.

Croda International (LON:CRDA – Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported GBX 142.60 ($1.82) earnings per share (EPS) for the quarter. Croda International had a net margin of 9.98% and a return on equity of 6.96%. As a group, equities research analysts expect that Croda International Plc will post 181.8307268 earnings per share for the current year.

Croda International Increases Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, April 10th will be issued a dividend of GBX 63 ($0.81) per share. This is a positive change from Croda International’s previous dividend of $47.00. This represents a yield of 2.03%. The ex-dividend date of this dividend is Thursday, April 10th. Croda International’s payout ratio is presently 93.66%.

About Croda International

(Get Free Report)

Founded in 1925 with the aim of turning bio-based raw materials into innovative ingredients, Croda International is a speciality chemicals company focused on consumer care and life sciences markets. The company is focused on creating, making and selling innovative ingredients that deliver real benefits to a diverse range of customers and employs more than 6,000 people around the world.